

1 **Functional analysis of NPHS1 mutations in Japanese**
2 **patients**

3

4 **Takayuki Miyai¹, Kunihiko Aya¹, Masanori Takaiwa¹, Kunimasa Yan², Yoshikazu Sado³,**
5 **Hiroyuki Tanaka⁴, Tsuneo Morishima¹**

6

7 **¹Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and**
8 **Pharmaceutical Sciences, Okayama, Okayama, Japan**

9 **²Department of Pediatrics, Kyorin University School of Medicine, Mitaka, Tokyo, Japan**

10 **³Division of Immunology, Shigei Medical Research Institute, Okayama, Okayama, Japan**

11 **⁴Department of Pediatrics, Okayama Saiseikai General Hospital, Okayama, Okayama,**
12 **Japan**

13

14

15

16 short running title: Functional analysis NPHS1 mutations

17

18 grants: The Japanese Society for Promotion of Science (18790721, 21591387, 24659499 to KA)

19

20 correspondence: Kunihiko Aya, 2-5-1 Shikata-cho, Okayama 700-8558 Japan

21 E-mail:kuniaya@okayama-u.ac.jp

22

23 **Keywords**

24 congenital nephrotic syndrome; nephrin; podocin; trafficking; transient transfection

25

25 **Short summary**

26 Background: Many mutations in the *NPHS1* gene were detected among patients with congenital
27 nephrotic syndrome. Functional analysis of those mutations was done with a stable-expression cell
28 line. Nevertheless, establishing such a cell line is time-consuming.

29 Methods and Results: We established an easier method using automatic counting software for
30 functional analysis with transient-transfection cells rather than a stable-expression cell line. We
31 demonstrated maltrafficking to the plasma membrane of abnormal nephrin for immunostaining on
32 transient-expression cells by comparison without Triton X (detecting proteins on the cell
33 membrane only) and with Triton X (detecting proteins both on the cell membrane and inside the
34 cell cytoplasm). We obtained relevant results with data obtained previously using a
35 stable-expression cell line. Furthermore, we conducted functional analysis of NPHS1 mutations in
36 Japanese patients with congenital nephrotic syndrome using this simple method, which revealed
37 that all pathogenic mutations impaired trafficking to the protein plasma membrane.

38 Conclusions: Functional analysis using transient-expression cells with automatic counting
39 software was useful to demonstrate maltrafficking to the plasma membrane of a protein. All
40 pathogenic mutations detected in Japanese patients impaired trafficking to the protein plasma
41 membrane.

42 **Introduction**

43 Nephrin, the main component protein of the podocyte slit diaphragm complex, plays a major
44 role in preventing protein loss into urine (Johnstone and Holzman, 2006). Two well-known
45 mutations cause Finnish-type congenital nephrotic syndrome (Kestila et al., 1998). The NPHS1
46 gene encodes nephrin protein. Earlier reports have described more than 100 mutations of this gene
47 detected worldwide in patients with congenital nephritic syndrome (Lenkkeri et al., 1999; Aya et
48 al., 2000; Koziell et al., 2002; Gigante et al., 2005; Sako et al., 2005; Heeringa et al., 2008; Aya et
49 al., 2009; Schoeb et al., 2010). In ordinary clinical situations, a mutation found in a patient is
50 believed to be causative when a substitution of amino acids causes a large change in the Grantham
51 score (Grantham R, 1974) and when a substituted amino acid is conserved among various species.
52 Results of functional analyses support that speculation.

53 Liu et al. (2001) examined functional analysis with cells that stably express a nephrin mutant.
54 However, establishing a stable-expressing cell line is time-consuming. This study examined
55 whether functional analysis using transient-expressing cells is useful or not. Functional analysis of
56 NPHS1 gene mutations found in Japanese patients was conducted using this method.

57

58

59

60

61

62

63

64

65

66

67

68

69 **Materials and methods**

70

71 *Plasmid and mutagenesis*

72 Plasmids were created with each mutation (Quick Change II XL Site-Directed Mutagenesis Kit;
73 Agilent Technologies Inc., CO, USA) according to the manufacturer's protocol with
74 pcDNA3-NPH1, which expresses human nephrin, as template. The primers used to create each
75 plasmid are shown in the table. Each plasmid was cycle-sequenced using Big-Dye terminators
76 (Applied Biosystems, CA, USA). The cycle sequence product was analyzed using an automated
77 sequencer (ABI Prism 310 Genetic Analyzer; Applied Biosystems).

78

79 *Cell culture and DNA transfection*

80 HEK293 cells were grown in Dulbecco's modified Eagle's medium high glucose (Life
81 Technologies Inc., CA, USA) supplemented with 10% fetal bovine serum. PDN8, a stable
82 HEK293 cell line expressing human podocin, was obtained as described previously (Nishibori et
83 al., 2004). PDN8 cells were grown in culture medium as described above by adding 200 µg/ml
84 Zeocin™ (Invitrogen Corp.). Plasmids expressing wild-type or mutated nephrin were transfected
85 into HEK293 and PDN8 cells according to the manufacturer's protocol (with Lipofectamine™
86 2000; Invitrogen Corp.).

87

88 *Western blotting*

89 HEK293 cells were cultured for 48 h after transient transfection with the plasmid cDNA of
90 wild-type or mutants. Cells were washed with phosphate-buffered saline (PBS) before addition of
91 hot sodium dodecyl sulfate (SDS) sample buffer [62.5 mM Tris-HCl pH 6.8, 2% SDS, 10%
92 glycerol, 0.01% bromophenol blue, 50 mM dithiothreitol, and proteinase inhibitor (Complete Mini
93 EDTA-free; Roche Diagnostics Corp., Mannheim, Germany)]. The cell lysates were collected
94 using a rubber scraper and were transferred into Eppendorf tubes. The lysates were sonicated,
95 boiled, and centrifuged for 10 min before loading. After all samples had been subjected to

96 SDS-polyacrylamide gel electrophoresis, the proteins were transferred onto nitrocellulose
97 membranes, which were blocked with Tris-buffered saline containing 5% bovine serum albumin
98 and 0.1% Tween-20. They were incubated with N20 anti-nephrin antibody (1:1000; Santa Cruz
99 Biotechnology Inc., CA, USA) overnight at 4 °C. The primary antibody was detected using
100 horseradish peroxidase-conjugated anti-goat Donkey IgG (Santa Cruz Biotechnology Inc.) and a
101 Western blot detection system (ECL plus; GE Healthcare UK Ltd., UK).

102 Two molecular standards were used for SDS-PAGE (Precision Plus Protein Standards, dual
103 color prestained, cat. no. 161-0374; Bio-Rad Laboratories Inc., CA, USA and Santa Cruz Marker
104 Molecular Weight Standard, cat. no. sc-2035; Santa Cruz Biotechnology Inc., CA, USA).

106 *Immunostaining*

107 HEK293 or PDN8 cells were cultured on glass cover slips and were transiently transfected with
108 the plasmid cDNA of wild-type NPHS1 or mutants. Because podocin is an anchor protein for
109 nephrin in the cell membrane, the PDN8 cells were used for experiments comparing nephrin on the
110 cell membrane and inside cells (Roselli S et al. 2002). The PDN8 cells were then cultured further
111 for 48 h. The cells were washed with PBS and fixed with 2% paraformaldehyde in PBS for 20 min
112 at room temperature. They were then incubated with 0.1% Triton X-100 in PBS for 5 min for
113 permeabilization to stain nephrin inside cells. Triton X-100 was not used for detection of nephrin
114 on the cell membrane.

115 The cells were incubated with N20 anti-nephrin antibody after incubation with the blocking
116 buffer (1% bovine serum albumin in PBS) for 10 min.

117 After washing with PBS, the cells were incubated with Alexa Fluor 488-conjugated donkey
118 anti-goat IgG (1:200) for 1 h at room temperature. Hoechst33342 was used as the nuclear stain for
119 the cells.

121 *Immunofluorescence microscopy and array scan*

122 All immunostained samples were examined using immunofluorescence microscopy (BZ-9000;

123 Keyence Co., Osaka, Japan). Nine fields were recorded with every plasmid.

124 Then, three independent experiments were performed. The Hoechst33342 positive cells
125 (showing all cells in that field) and Alexa 488 positive cells (showing cells expressing nephrin) in
126 the immunofluorescence microscope images were counted using Cellomics BioApplications
127 (Colocalization Ver.3.0; Thermo Fisher Scientific Inc., MA, USA).

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150 **Results**

151

152 *Confirmation of anti-nephrin antibody performance*

153 To confirm the antibody performance, immunofluorescence staining was performed with
154 anti-nephrin antibodies. The HEK293-cell transiently transfected plasmid expresses wild-type
155 nephrin, p.Glu246*mutant, or no nephrin. The HEK293 was used for confirmation of antibody
156 performance (Fig. 1). With N20 antibody, wild nephrin and p.Glu246*mutant were stained. N20
157 anti-nephrin antibody was used to detect wild-type nephrin and mutants.

158

159 *Molecular size of nephrin mutants*

160 Using cell lysates containing not only wild-type nephrin but also missense mutants, bands around
161 185 kD were detected using Western blot with anti-nephrin antibody, as reported previously for
162 wild nephrin (data not shown). Truncated mutants p.Asp827* (c.2479C > T in exon18) and
163 p.Gln839fs*8 (c.2515delC in exon 19) each had molecular weight of around 120 kD. The
164 truncated mutant p.Glu246* (c.736G > T in exon 7) had molecular weight of around 30 kD.

165

166 *Expression pattern of wild nephrin*

167 Wild-type nephrin was expressed along the outline in many cells (Fig. 2). No difference was found
168 in the ratio of Alexa488 positive cells to Hoechst 33342 cells between those with and without
169 Triton X-100.

170 The ratio of cells expressing wild nephrin on the cell surface to cells expressing wild nephrin
171 *in* and *on* a whole cell (i.e. the on–in ratio) was almost 1 (Fig. 3). This result indicates that
172 wild-type nephrin was trafficking to cell membranes in cells that express nephrin inside once.

173

174 *Comparison of stably and transiently expressing cells with the same mutants*

175 Preliminarily, mutants already examined in earlier studies (Liu et al., 2001) using the
176 stable-expression cell line below were used for certification of this transient-expression method:

177 p.Ile171Asn mutant, with defect of trafficking to the cell surface; p.Leu376Val mutant, without
178 defect of trafficking; p.Arg743Cys mutant, without a problem of trafficking, which shows a mild
179 clinical course; and p.Arg1140Cys mutant, without defect of trafficking, which has an intracellular
180 mutation site.

181 The ratio of the number of cells detected using anti-nephrin antibody without Triton X to
182 those with Triton X (on-in ratio) was found using Cellomics BioApplications. Three experiments
183 were performed independently, all showing similar on-in ratios. Herein, we present the average of
184 three independently obtained experiment results (Fig. 3).

185 The on-in ratio of p.Leu376Val mutant was 0.84. The on-in ratio of p.Arg743Cys mutant was
186 0.92. The on-in ratio of p.Arg1140Cys mutant was 1.11. That of p.Ile171Asn mutant was 0.36.
187 The trend of the on-in ratio of these four mutants in transient transfected cells is compatible with
188 functional analysis using a stably expressing cell line (Liu et al., 2001).

189
190 *Functional analysis of NPHS1 mutations from Japanese patients*

191 The on-in ratio with transient transfection method on each mutant from Japanese patients (Aya et
192 al., 2000; Aya et al., 2009) is shown in Figure 3. The values are averaged results derived from
193 those obtained from three independent experiments. First, p.Glu246*, p.Arg827*, and
194 p.Gln839fs*8 (c.2515delC) are truncated mutants. The on-in ratios of the truncated mutants are
195 small: around 0.40. The ratios of truncated mutants are nearly equal to the ratio of p.Ile171Asn.

196 These data indicate that these three truncated mutants have defects of trafficking to the cell
197 surface. Aside from the on-in ratio, few fluorescence-positive cells with Triton X-100 have
198 protein detected with anti-nephrin antibody both on and in.

199 Earlier reports (Aya et al., 2000; Aya et al., 2009) have described that four missense mutants
200 are causative: p.Cys160Ser, p.Arg379Trp, p.Gly601Arg, and p.Val819Asp. The on-in ratios of
201 these four missense mutants are also small. In contrast, the on-in ratio of p.Glu447Lys, which is
202 not so causative, is nearly 1 (0.87). These data show that causative mutants detected in Japanese
203 patients with congenital nephrotic syndrome have defects of trafficking to cell membranes.

204

205 **Discussion**

206

207 Liu et al. (2001) reported that functional analysis of nephrin mutants in cultured cells was
208 performed with a stable-expressing cell line. However, because establishment of a
209 stable-expressing cell line is time-consuming, this mode of using a stable cell line is unsuitable for
210 analysis of each mutant detected in patients. Our method of using software for automatic analysis
211 of transient-expressing cells is not time-consuming.

212 Liu et al. (2001) reported the p.Ile171Asn mutant with the difficulty of trafficking to the cell
213 surface. In the transient transfection experiment reported herein, p.Ile171Asn mutant was shown to
214 have a low rate of expression on the cell surface, which is compatible with results described in
215 Liu's report: p.Leu376Val, p.Arg743Cys, and p.Arg1140Cys mutants show no difficulty of
216 trafficking to the cell surface (Fig. 2). In this experiment, these mutants have a high rate (higher
217 than 0.8) of expression on the cell surface (Fig. 3).

218 Among seven missense mutations detected in Japanese patients, four mutations are inferred to
219 be pathogenic: p.Cys160Ser, p.Arg379Trp, p.Gly601Arg, and p.Asp819Val. The four mutants
220 have low rates of expression on the cell surface. Moreover, they have difficulty with trafficking to
221 the cell surface (Fig. 3).

222 The p.Glu447Lys mutant, which is not regarded as pathogenic, has a high rate of expression
223 on the cell surface. It presents no difficulty with trafficking to the cell surface (Fig. 3).

224 The strength of fluorescence itself is influenced by nephrin production capability, degradation
225 with mutated protein, affinity of the anti-nephrin antibody to each mutant nephrin, and other
226 factors. In the case of the three truncated mutants, few fluorescence-positive cells with Triton
227 X-100 have protein detected with anti-nephrin antibody both on and in the cell. Therefore, it is
228 difficult to ascertain whether the small number of fluorescence-positive cells without Triton X-100
229 on cells is attributable to the difficulty of trafficking to the cell surface or to other factors such as
230 low nephrin production capability. However, calculating the ratio of the quantity of fluorescence

231 for the cell surface and for the whole cell can resolve that issue.

232 The three truncating mutations detected in Japanese patients exhibit problems with trafficking
233 to the cell surface, although some defects aside from trafficking to the cell surface might
234 contribute to pathogenesis in these patients.

235 The on–in ratios of four missense mutants that are regarded as pathogenic and three truncating
236 mutants from Japanese patients and p.Ile171Asn mutant were 0.4–0.6 (Fig. 3). The on–in ratios of
237 p.Glu447Lys and three missense mutants without problems of trafficking to the cell surface
238 described in Liu’s report were higher than 0.8 (Fig. 3).

239 In conclusion, transient transfection is useful for the functional analysis of nephrin.

240

241 **Acknowledgements**

242 This work was supported in part by grants-in-aid from the Japanese Society for Promotion of
243 Science (18790721, 21591387, 24659499 to KA).

244 A part of this study was published in abstract form (Pediatr Nephrol 2010; 25: 1917–1918).

245

246 **Disclosure/Duality of Interest**

247 None declared.

248

249

- 250 1. Aya K., Tanaka H. and Seino Y. (2000). Novel mutation in the nephrin gene of a Japanese
251 patient with congenital nephrotic syndrome of the Finnish type. *Kidney Int.* 57, 401-404.
252
- 253 2. Aya K., Shimizu J., Ohtomo Y., Satomura K., Suzuki H., Yan K., Sado Y., Morishima T.
254 and Tanaka H. (2009). *NPHS1* gene mutation in Japanese patients with congenital
255 nephrotic syndrome. *Nephrol. Dial. Transplant.* 24, 2411-2414.
256
- 257 3. Gigante M., Greco P., Defazio V., Lucci M., Margaglione M., Gesualdo L. and Iolascon A.
258 (2005) Congenital nephrotic syndrome of Finnish type: detection of new nephrin mutations
259 and prenatal diagnosis in an Italian family. *Prenat. Diagn.* 25, 407-410.
260
- 261 4. Grantham R. (1974). Amino acid difference formula to help explain protein evolution.
262 *Science* 185, 862-864.
263
- 264 5. Heeringa S.F., Vlangos C.N., Chernin G., Hinkes B., Gbadegesin R., Liu J., Hoskins B.E.,
265 Ozaltin F. and Hildebrandt F. (2008). Thirteen novel *NPHS1* mutations in a large cohort of
266 children with congenital nephrotic syndrome. *Nephrol. Dial. Transplant.* 23, 3527-3533.
267
- 268 6. Johnstone D.B. and Holzman L.B. (2006). Clinical impact of research on the podocyte slit
269 diaphragm. *Nat. Clin. Pract. Nephrol.* 2, 271-282.
270
- 271 7. Kestila M., Lenkkeri U., Mannikko M., Lamerdin J., McCready P., Putaala H.,
272 Ruotsalainen V., Morita T., Nissinen M., Herva R., Kashtan C.E., Peltonen L., Holmberg
273 C., Olsen A. and Tryggvason K. (1998). Positionally cloned gene for a novel glomerular
274 protein – nephrin – is mutated in congenital nephrotic syndrome. *Mol. Cell.* 1, 575-582.
275
- 276 8. Koziell A., Grech V., Hussain S., Lee G., Lenkkeri U., Tryggvason K. and Scambler P.
277 (2002). Genotype/phenotype correlations of *NPHS1* and *NPHS2* mutations in nephrotic
278 syndrome advocate a functional inter-relationship in glomerular filtration. *Hum. Mol.*
279 *Genet.* 11, 379-388.
280
- 281 9. Lenkkeri U., Mannikko M., McCready P., Lamerdin J., Gribouval O., Niaudet P.M.,
282 Antignac C.K., Kashtan C.E., Homberg C., Olsen A., Kestila M. and Tryggvason K.
283 (1999). Structure of the gene for congenital nephrotic syndrome of the Finnish type
284 (*NPHS1*) and characterization of mutations. *Am. J. Hum. Genet.* 64, 51-61.
285
- 286 10. Liu L., Done S.C., Khoshnoodi J., Bertorello A., Wartiovaara J., Berggren P.O. and
287 Tryggvason K. (2001). Defective nephrin trafficking caused by missense mutations in the
288 *NPHS1* gene: insight into the mechanisms of congenital nephrotic syndrome. *Hum. Mol.*
289 *Genet.* 10, 2637-2644.
290
- 291 11. Nishibori Y., Nishibori Y., Liu L., Hosoyamada M., Endou H., Kudo A., Takenaka H.,
292 Higashihara E., Bessho F., Takahashi S., Kershaw D., Ruotsalainen V., Tryggvason K.,
293 Khoshnoodi J. and Yan K. (2004). Disease-causing missense mutations in *NPHS2* gene
294 alter normal nephrin trafficking to the plasma membrane. *Kidney Int.* 66, 1755-1765.
295
- 296 12. Roselli S., Gribouval O., Boute N., Sich M., Benessy F., Attié T., Gubler M.C. and
297 Antignac C. (2002). Podocin localizes in the kidney to the slit diaphragm area. *Am. J.*
298 *Pathol.* 160, 131-139.
299
- 300 13. Sako M., Nakanishi K., Obana M., Yata N., Hoshii S., Takahashi S., Wada N., Takahashi

301 Y., Kaku Y., Satomura K., Ikeda M., Honda M., Iijima K. and Yoshikawa N. (2005).
302 Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital
303 nephrotic syndrome. *Kidney Int.* 67, 1248-1255.

304
305 14. Schoeb D.S., Chernin G., Heeringa S.F., Matejas V., Held S., Vega-Warner V.,
306 Bockenhauer D., Vlangos C.N., Moorani K.N., Neuhaus T.J., Kari J.A., Macdonald J.,
307 Saisawat P., Ashraf S., Ovunc B., Zenker M. and Hildebrandt F. (2010). Nineteen novel
308 NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome
309 (CNS). *Nephrol. Dial. Transplant.* 25, 2970-2976.
310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332 **Figure Legends**

333

334 Fig. 1 Immunostaining for HEK293 cell transfected.

335 HEK293 cells expressing wild-type nephrin and p.Glu246* mutant were immunostained with
336 N20 antibody, with addition of Triton X-100. (magnification $\times 200$)

337

338 Fig. 2 Immunostaining for PDN8 transfected with each vector.

339 Transfected cells were immunostained with Hoechst33342 and N20 anti-nephrin antibody
340 (left panels) without Triton X-100 and (right panels) with Triton X-100: a) wild nephrin; b)
341 empty vector; c) p.Ile171Asn mutant, maltrafficking, already demonstrated in Liu's study; d)
342 p.Arg743Cys mutant, not maltrafficking, already demonstrated in Liu's study; e)
343 p.Cys160Ser mutant, putatively pathogenic mutation; f) p.Glu447Lys mutant, putatively
344 non-pathogenic mutation; g) p.Asp819Val mutant, putatively pathogenic mutation; h)
345 p.Glu246*, non-sense mutation; and i) c.2515delC, frameshift mutant. (magnification $\times 200$)

346

347 Fig. 3 On-in ratios of nephrin.

348 Ratios of Alexa488 positive cells to Hoechst 33342 cells with and without Triton X-100
349 (on-in ratio). Mutations showing low ratios were p.Cys160 Ser, p.Glu246*, p.Arg379Trp,
350 p.Asp819Val, p.Asp827*, and c.2515delC, in addition to p.Ile171Asn.

351

352

353

354

355

356

357

358


359 Table primer sets for mutagenesis

Mutation		Primer
p.Cys160Ser	F	5'-ggtagctgcgtggtcaactctgtgtctgggg-3'
(c.479G>C)	R	5'-ccccagacacagagttgaccaccagctacc-3'
p.Ile171Asn	F	5'-gccagcacctgacaacaccattctcc-3'
(c.512T>A)	R	5'-ggagaatgggtgtgtcaggtgctggc-3'
p.Glu246*	F	5'-ggaccccctgtcatctagtggccaggcctgg-3'
(c.736G>T)	R	5'-ccaggcctggccactagatgacaggggggtcc-3'
p.Leu376Val	F	5'-gctacgatgggtgggtgggctggcggc-3'
(c.1126C>G)	R	5'-gccgccagcccaccaccatcgtagc-3'
p.Arg379Trp	F	5'-ggtggctgggctggtggcagctgctgccc-3'
(c.1135C>T)	R	5'-gggcagcagctgccaccagcccagccacc-3'
p.Glu447Lys	F	5'-gccagaaactgtggattaagggtccccag-3'
(c.1339G>A)	R	5'-ctgggggacccttaatccacagtttctgggc-3'
p.Gly601Arg	F	5'-ggagagccccattcaaacgctccgccgcc-3'
(c.1801G>C)	R	5'-ggcggcggcggagcgtttgaatggggctctcc-3'
p.Arg743Cys	F	5'-gctcccaccatctgtgccctccaggacccc-3'
(c.2227C>T)	R	5'-ggggtcctggagggcacagatggtgggagc-3'
p.Asp819Val	F	5'-ccagtgcattgtgtcaatggggtggcgc-3'
(c.2456A>T)	R	5'-gcgccaccccattgaccacaatgcaactgg-3'
p.Arg827*	F	5'-ggggtggcgcctccagcatgacggctgctcc-3'
(c.2779C>T)	R	5'-ggagcagccgtcatgctggaggcgcacccc-3'
p.Gln839fs*8	F	5'-gtcagattgccccagggtggagcacccc-3'
(c.2515delC)	R	5'-ggggtgctccacctgggggcaaactgtac-3'
p.Arg1140Cys	F	5'-ggcagagccgtattactgctccctgaggg-3'
(c.3418C>T)	R	5'-ccctcagggagcagtaatacggctctgcc-3'


360

361


Figure 1



Wild






p.Glu246*



Vector

Figure 2





Nephrin	On-in ratio
Wild	0.97
p.Cys160Ser	0.34
p.Ile171Asn	0.36
p.Glu246*	0.40
p.Leu376Val	0.84
p.Arg379Trp	0.39
p.Glu447Lys	0.87
p.Gly601Arg	0.60
p.Arg743Cys	0.92
p.Asp819Val	0.49
p.Arg827*	0.41
c.2515delC	0.33
p.Arg1140Cys	1.11
Empty vector	1.09